Literature DB >> 2546744

Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme.

G K Stalla1, J Stalla, K von Werder, O A Müller, R Gerzer, V Höllt, K H Jakobs.   

Abstract

Nitroimidazole derivatives dose-dependently decreased basal and CRF-stimulated ACTH release, basal and GRF-stimulated rat GH release, and basal rat PRL release in primary cultures of rat anterior pituitary cells. In addition, basal and CRF-stimulated mRNA coding for the ACTH precursor were reduced after preincubation with the nitroimidazole derivatives. Miconazole, econazole, isoconazole, clotrimazole, and bifonazole had similar or more pronounced effects on anterior pituitary function compared to ketoconazole, whereas metronidazole and etomidate were less effective. The positive correlation between the number of phenylated side-chains or phenolic rings of the imidazole molecule and the efficacy to inhibit activity on pituitary hormone secretion suggests a structure-activity relationship of these compounds. The effects of the nitroimidazole derivatives on anterior pituitary hormone release and biosynthesis were mediated by cAMP. Thus, basal and CRF-, cholera toxin-, and forskolin-stimulated adenylate cyclase activities in rat anterior pituitary cell membranes determined by cAMP formation were suppressed by the nitroimidazole derivatives. Pertussis toxin did not diminish the nitroimidazole derivative effect on cAMP formation. The adenylate cyclase inhibitory effect of these substances was independent of the presence of GTP in the assay system, underlining a direct effect on the catalytic subunit. In addition, basal and forskolin-stimulated cAMP generation in membranes of S49 lymphoma cyc-variants, which lack a functional Gs protein, was efficiently suppressed (by up to 90%) by the nitroimidazole derivatives. In conclusion, ketoconazole and other nitroimidazole derivatives inhibit anterior pituitary hormone synthesis and secretion apparently by a direct effect on the catalytic subunit of the adenylate cyclase system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546744     DOI: 10.1210/endo-125-2-699

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

2.  Activation of adenylate cyclase during swelling of S49 cells in hypotonic medium is not involved in subsequent volume regulation.

Authors:  P A Watson; K E Giger; C M Frankenfield
Journal:  Mol Cell Biochem       Date:  1991 May 29-Jun 12       Impact factor: 3.396

3.  Characterization of Interleukin-2 (IL-2) receptor expression and action of IL-2 and IL-6 on normal anterior pituitary cell growth.

Authors:  E Arzt; J Sauer; R Buric; J Stalla; U Renner; G K Stalla
Journal:  Endocrine       Date:  1995-02       Impact factor: 3.633

4.  Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole.

Authors:  James Simpson; Adrienn Pálvölgyi; Ferenc A Antoni
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-01-03       Impact factor: 3.000

5.  Interleukin-2 and interleukin-2 receptor expression in human corticotrophic adenoma and murine pituitary cell cultures.

Authors:  E Arzt; G Stelzer; U Renner; M Lange; O A Müller; G K Stalla
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

6.  Liposomes targeted to deliver antisecretory agents to jejunal mucosa.

Authors:  R R Uwiera; D A Romancyia; J P Wong; G W Forsyth
Journal:  Can J Vet Res       Date:  1992-07       Impact factor: 1.310

Review 7.  Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas.

Authors:  Marta Labeur; Marcelo Paez-Pereda; Eduardo Arzt; Günter K Stalla
Journal:  Rev Endocr Metab Disord       Date:  2008-07-07       Impact factor: 6.514

8.  Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics.

Authors:  Carlotta Pozza; Chiara Graziadio; Elisa Giannetta; Andrea Lenzi; Andrea M Isidori
Journal:  J Oncol       Date:  2012-08-09       Impact factor: 4.375

9.  Hypoxia and the hypoxia inducible factor 1α activate protein kinase A by repressing RII beta subunit transcription.

Authors:  Kristin Lucia; Yonghe Wu; Jose Monteserin Garcia; Anne Barlier; Michael Buchfelder; Wolfgang Saeger; Ulrich Renner; Günter K Stalla; Marily Theodoropoulou
Journal:  Oncogene       Date:  2020-02-28       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.